MS
RLMD icon

Murray Stahl’s Relmada Therapeutics RLMD Stock Holding History

Murray Stahl’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$97.2K – 356
2024
Q3 		$97.2K Hold
30,000
– – ﹤0.01% 330
2024
Q2 		$90K Hold
30,000
– – ﹤0.01% 312
2024
Q1 		$140K Hold
30,000
– – ﹤0.01% 295
2023
Q4 		$124K Buy
+30,000
New +$88.8K ﹤0.01% 297

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Murray Stahl's RLMD Position: Q4 2024 in Review

Murray Stahl sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 30,000 shares — an estimated $97.2K sold.

Murray Stahl first reported a position in RLMD in Q4 2023 and held it in 4 quarters. The position peaked at $140K in Q1 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Murray Stahl reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Murray Stahl sold 30,000 Relmada Therapeutics shares in Q4 2024, an estimated $97.2K.
  • Murray Stahl first reported a position in Relmada Therapeutics in Q4 2023 and held it in 4 quarters.
  • Murray Stahl's Relmada Therapeutics position peaked at $140K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Horizon Kinetics Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.